Beruflich Dokumente
Kultur Dokumente
Employment for This law, enacted April 9, 2010, established specific goals for programs to assist
Individuals with individuals with Autism to obtain and sustain employment. The program goal include,
Autism 7 - Virginia skills training, behavioral support, and education.
The Patient ACA establishes a Cures Acceleration Network (CAN) and appropriates $500 million to
Protection and CAN for fiscal year 2010.
Affordable Care The goals of CAN are to:
Act (ACA) 8 -
Federal 1. Promote innovation in technologies to support the advanced research and
development and production of High Need Cures; 9
1
AUTISM SOCIETY, ABOUT AUTISM, available at www.autism-society.org/site/PageServer?pagename=about_home (last accessed June
2010).
2
SHIMABUKURO TT, GROSSE SD, RICE C, Medical expenditures for children with an autism spectrum disorder in a privately insured
population, J. OF AUTISM DEVELOPMENTAL DISORDERS (2007), available at www.ncbi.nlm.nih.gov/pubmed/17690969 (last accessed June
2010).
3
Unless otherwise cited: INDIVIDUALS WITH DISABILITIES EDUCATION ACT DATA (2008), available at www.ideadata.org/PartBChildCount.asp (last
accessed June 2010).
4
Derek Kravitz, Fairfax: Autism, not 'baby boomers,' biggest future health challenge, THE WASH. POST, (May 18, 2010), available at
voices.washingtonpost.com/virginiapolitics/2010/05/fairfax_autism_not_baby_boomer.html (last accessed June 2010).
5
INDIVIDUALS WITH DISABILITIES EDUCATION ACT DATA (2008), available at www.ideadata.org/PartBChildCount.asp (last accessed June 2010).
Ages 3-21. U.S data unavailable after 2006.
6
Brian Chellgren & Michelle Coughlin, THE CURES ACCELERATION NETWORK: A HIDDEN GEM WITHIN THE PATIENT PROTECTION AND AFFORDABLE CARE
ACT, ABA. Vo. 6, No. 9 (May 2010), available at www.abanet.org/health/esource/Volume6/09/Chellgren.html#_ftn3 (last accessed June
2010).
7
V.A. Chap. 0307 (2010), available at http://leg1.state.va.us/cgi-bin/legp504.exe?101+ful+CHAP0307 (last accessed Aug. 2010).
8
Pub. L. No. 111-148, 124 Stat. 119 (2010).
9
High Need Cures are a drug, biological product, or device that, in the determination of the Director of NIH—(A) is a priority to
diagnose, mitigate, prevent, or treat harm from any disease or condition; and (B) for which the incentives of the commercial market
are unlikely to result in its adequate or timely development. Ibid.